For research and educational purposes only. Not medical advice.
Semaglutide (compounded) Reference
Educational, not medical advice reference for Semaglutide (compounded): GLP-1, Fat Loss; regulatory status, evidence posture, source review, and…
Reference summary
pepSmart uses approved-label semaglutide schedules only as reference context; compounded vial concentration and syringe-unit instructions must come from the prescriber or dispensing pharmacy.
Regulatory and posture
- Categories
- GLP-1, Fat Loss
- Aliases
- Semaglutide, Wegovy label reference, Ozempic active ingredient
- Evidence posture
- human
- Regulatory status
- Compounded semaglutide is not FDA-approved. FDA-approved semaglutide label references exist for branded products, including Wegovy injection and Wegovy HD 7.2 mg for certain adults. The FDA semaglutide shortage was resolved in February 2025; with semaglutide off the shortage list, large-scale compounding of copies is restricted, and in April 2026 the FDA proposed excluding semaglutide from the 503B outsourcing-facility bulks list (public comment open through June 29, 2026). Patient-specific 503A compounding remains the narrow lawful pathway.
- Content review status
- approved label reference
Selected public sources
- Novo Nordisk Wegovy dosing reference
- Novo Nordisk Wegovy safety profile
- FDA Wegovy HD 7.2 mg approval announcement
- FDA: proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (April 2026)
- FDA concerns with unapproved GLP-1 drugs
Related tools
- GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
- GLP-1 ramp planner - Preview a linear educational dose-step table.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
- GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.
- Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.